JP Morgan Chase’s RxSight RXST Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.98M Buy
488,641
+236,043
+93% +$1.96M ﹤0.01% 3785
2025
Q4
$2.63M Buy
252,598
+149,716
+146% +$1.5M ﹤0.01% 3871
2025
Q3
$925K Buy
102,882
+68,735
+201% +$603K ﹤0.01% 4649
2025
Q2
$444K Sell
34,147
-128,656
-79% -$1.93M ﹤0.01% 4846
2025
Q1
$4.11M Buy
162,803
+128,406
+373% +$3.82M ﹤0.01% 3329
2024
Q4
$1.18M Sell
34,397
-158,113
-82% -$7.13M ﹤0.01% 4513
2024
Q3
$9.52M Buy
192,510
+7,494
+4% +$384K ﹤0.01% 2646
2024
Q2
$11.1M Sell
185,016
-125,944
-41% -$7.2M ﹤0.01% 2366
2024
Q1
$16M Sell
310,960
-285,580
-48% -$14M ﹤0.01% 2073
2023
Q4
$24.1M Buy
596,540
+44,975
+8% +$1.32M ﹤0.01% 1694
2023
Q3
$15.4M Buy
551,565
+11,431
+2% +$341K ﹤0.01% 1884
2023
Q2
$15.6M Sell
540,134
-25,372
-4% -$564K ﹤0.01% 1902
2023
Q1
$9.43M Buy
565,506
+553,820
+4,739% +$7.82M ﹤0.01% 2334
2022
Q4
$148K Buy
11,686
+434
+4% +$5.28K ﹤0.01% 5185
2022
Q3
$135K Buy
11,252
+243
+2% +$3.34K ﹤0.01% 5146
2022
Q2
$155K Buy
11,009
+2,782
+34% +$36.7K ﹤0.01% 5201
2022
Q1
$102K Buy
8,227
+2,820
+52% +$33.9K ﹤0.01% 5501
2021
Q4
$61K Buy
5,407
+1,362
+34% +$16.4K ﹤0.01% 5869
2021
Q3
$51K Buy
+4,045
New +$55.7K ﹤0.01% 5837

Other funds holding RXST

JP Morgan Chase's RXST Position: Q1 2026 in Review

JP Morgan Chase increased its RxSight (RXST) stake by 93% in Q1 2026, buying an estimated $1.96M and bringing the position to 488,641 shares worth $2.98M. The position accounts for ﹤0.01% of the portfolio, ranked #3785.

JP Morgan Chase first reported a position in RXST in Q3 2021 and has held it in 19 quarters since. The position peaked at $24.1M in Q4 2023. 164 funds tracked by Wall St. Rank hold RXST as of Q1 2026.

  • JP Morgan Chase held 488,641 shares of RxSight worth $2.98M as of Q1 2026.
  • JP Morgan Chase bought 236,043 RxSight shares in Q1 2026, an estimated $1.96M.
  • RxSight made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #3785 holding.
  • JP Morgan Chase first reported a position in RxSight in Q3 2021 and has held it in 19 quarters since.
  • JP Morgan Chase's RxSight position peaked at $24.1M in Q4 2023.
  • 164 funds tracked by Wall St. Rank held RxSight as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.